Appeal Proceedings on European VisionBlue Patent Stayed; Patent Remains in Force
...tion in 1983, D.O.R.C. has developed into a market leader
in research, development and production of products for eye surgery,
especially products for
vitreoretinal and cataract surgery. Our products are
used by eye surgeons worldwide, because of the high quality development and
because our products are known for ...
Eye Disease, Cognitive Decline Linked in Study
...ssor, department of ophthalmology, Centre for Eye Research Australia, The University of Melbourne, Victoria, Australia; Demetrios Vavvas, M.D., Ph.D.,
vitreoretinal surgeon, Massachusetts Eye and Ear Infirmary, Boston, and principal investigator, angiogenesis laboratory, Harvard Medical School, Boston; May 2009 ...
Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors
...The presentation will feature James M. Maisel M.D. and Joanna J. Oda, M.D.,
vitreoretinal specialists from the Retina Group of New York. As people live longer, they...etina Group of New York
The Retina Group of New York has provided tertiary
vitreoretinal care to patients in Nassau and Suffolk Counties since 1986 at its offices i...
Crystalens HD(TM) Receives FDA Approval
...any has one of the oldest, best
known and most respected healthcare brands in the world. Bausch & Lomb
offers a full suite of products in cataract and
vitreoretinal surgery
including intraocular lenses and delivery systems, phacomulsification
equipment and other surgical instruments and devices. To learn more abou...
Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical
...sible for managing all functional areas including
surgical instrumentation, intraocular lenses and disposable devices used in
cataract, refractive and
vitreoretinal procedures.
Prior to Alcon's acquisition of CooperVision in 1989, Mr. Caldwell
served in several leadership positions with CooperVision and Cavitron...
Gene therapy safety trial for childhood blindness under way
...al. Byrne is the principal investigator at UF.
The actual medical technique used to transfer the gene is not unusual, said Kaushal, who directs the
vitreoretinal service in the UF College of Medicine.
The procedure involves two incisions that give the surgeon access to the surface of the retina, Kaushal said...
Digital Healthcare Announces Appointment of Dr. Suber Huang as Medical Director
...Vice Chairman in the Department of Ophthalmology and Visual
Sciences, University Hospitals Case Medical Center, Cleveland, Ohio. He is
the Director of
vitreoretinal Diseases and Surgery, the Director of
Clinical Research, and the Director of the Retinal Diseases Image Analysis
Reading Center (REDIARC). Dr. Huang s...
Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements
...s a major cause of central visual loss and is one of the leading causes of blindness in people over 60.
Dr. David M. Brown, retinal surgeon with
vitreoretinal Consultants at The Methodist Hospital, is lead author on the ANCHOR study and a secondary author on the MARINA study. Brown enrolled more patients tha...
Radiation therapy effective against Eye cancer
... Kathryn Greven, Radiation oncologist and Craig Greven,
vitreoretinal surgeon, Wake Forest University have been treating patients with malignant melanoma of uvea with radiation therapy. Uveal malignant melanoma// is a ra...
Vitreoretinal in Medical Technology
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
...pment for the non-surgical treatment of back
of the eye diseases. Microplasmin is also being evaluated in Phase II
clinical development for additional
vitreoretinal indications and as a
potential therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
...pment for the non-surgical treatment of back
of the eye diseases. Microplasmin is also being evaluated in Phase II
clinical development for additional
vitreoretinal indications and as a
potential therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
...pment for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional
vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
...pment for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional
vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
...pment for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional
vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
...ease and cancer. The Company has several programs in Phase II
clinical development including microplasmin, which is being evaluated as a
treatment for
vitreoretinal disorders and as a thrombolytic agent for
vascular occlusive diseases. ThromboGenics is also developing novel
antibody therapeutics in collaboration w...
MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
...in U. Dugel, M.D., member of MacuSight's scientific advisory board,
managing partner, Retinal Consultants of Arizona, Phoenix AZ, clinical
instructor,
vitreoretinal diseases and surgery, department of
ophthalmology, University of Arizona, and the study's lead investigator.
As part of the design of this randomize...
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
...biological activity of sirolimus administered through
subconjunctival injection are very exciting," stated Pravin U. Dugel, M.D.,
clinical instructor,
vitreoretinal diseases and surgery, department of
ophthalmology, University of Arizona, partner at Retinal Consultants of
Arizona in Phoenix, Arizona, and the study...
Vitreoretinal in Medical Products
Micro Vitreoretinal Cannula Angled
Description: Micro
Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
Company:Oasis Medical
BD Visitec Vitreoretinal Cannulas
Description: Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
Company:BD Ophthalmics
clariVit Central Mag.
Description:... This patented lens offers high resolution by far surpassing any medium magnification
vitreoretinal surgical lens in stereopsis, brilliance and clarity, detailed visualization to the equatorial regions, vitrectomy in diabetics, membrane peeling exten...
Company:Volk Optical, Inc.
Surgical Viewing System
Description:...e most technologically advanced wide angle viewing system available for the
vitreoretinal surgeon. Its unique single-element prism design, numerous advanced features...e-field viewing capability have made it the #1 panoramic viewing system for
vitreoretinal surgery since its introduction....
Company:Volk Optical, Inc.
Mini Quad® XL
Description:... MiniQuad XL is recommended for evaluating
vitreoretinal relationships of the entire fundus and in the management of dislocated lenses. It is the ideal lens for small pupil fundus viewing with the operating ...
Company:Volk Optical, Inc.
PeaceKeeper Extrusion Aspiration Cannula Eraser Instrument
Description:...sis with extrusion aspiration and backflush functionality in a single use, sterile instrument, the PeaceKeeper delivers exceptional value, utility and
vitreoretinal surgical performance....
Company:Medtronic Ophthalmics
Eftiar Octane
Description:... Eftiar offers the
vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and c...
Company:Dutch Ophthalmic, USA
Perfluoron Liquid
Description:... Welcome to a new dimension in
vitreoretinal surgery.
By using Perfluoron, a liquid tool composed of purified perfluoro-n-octane, you can greatly expand your surgical capabilities. Perfluoron ...
Company:Alcon Laboratories
Hexon Illumination System - 1266 XII
Description:...amp, a more efficient source of high quality illumination. This exceptional illumination quality provides a color consistency which is well suited for
vitreoretinal surgery.
D.O.R.C. has also responded to clinical concerns regarding minimizing the incidence of phototoxicity, especially when surgical conditions dic...
Company:Dutch Ophthalmic, USA
Harmony Special Peristaltic IV
Description:...ctions. The Harmony Special Peristaltic is designed to meet the needs of any practice setting with the possibility to add special options for advanced
vitreoretinal surgery....
Company:Dutch Ophthalmic, USA
More>>
Vitreoretinal in Medical Dictionary
Detached retina
...d about causes, symptoms and treatment of a detached retina , which requires prompt action to prevent permanent vision loss. Vitrectomy and
vitreoretinal eye surgery can help treat retinal detachments ... Detached retina . Diabetic retinopathy. Diabetic retinopathy - eye doctor Q&A ... ...
Vitreoretinal in Biological Technology
ThromboGenics NV: Business Update
...pment for the non-surgical treatment of back
of the eye diseases. Microplasmin is also being evaluated in Phase II
clinical development for additional
vitreoretinal indications and as a
potential therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics Announces Business Update and 2008 Full Year Results
...pment for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional
vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
...pment for the non-surgical treatment of back of the eye
diseases. Microplasmin is also being evaluated in Phase II clinical
development for additional
vitreoretinal indications and as a potential
therapy for stroke. ThromboGenics is also developing novel antibody
therapeutics in collaboration with BioInvent Intern...
Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
... occurs in these animals," said Raymond Iezzi,
M.D., M.S., Scientific Director, Ligon Research Center of Vision, Assistant
Professor of Ophthalmology,
vitreoretinal Service, Kresge Eye Institute, Wayne
State University School of Medicine.
"These results were considered compelling enough to warrant a huma...
ThromboGenics N.V.: Business Update
...ease and cancer. The Company has several programs in Phase II
clinical development including microplasmin, which is being evaluated as a
treatment for
vitreoretinal disorders and as a thrombolytic agent in
stroke. ThromboGenics is also developing novel antibody therapeutics in
collaboration with BioInvent Internat...
ThromboGenics Announces Half Year Results 2008
...ease and cancer. The Company has several programs in Phase II
clinical development including microplasmin, which is being evaluated as a
treatment for
vitreoretinal disorders and as a thrombolytic agent for
vascular occlusive diseases. ThromboGenics is also developing novel
antibody therapeutics in collaboration w...
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
...ease and cancer. The Company has several programs in Phase II
clinical development including microplasmin, which is being evaluated as a
treatment for
vitreoretinal disorders and as a thrombolytic agent for
vascular occlusive diseases. ThromboGenics is also developing novel
antibody therapeutics in collaboration w...
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
...nd eye diseases. The Company has several programs in Phase II clinical
development including microplasmin, which is being evaluated as a treatment
for
vitreoretinal disorders and as a thrombolytic agent for vascular
occlusive diseases, including acute stroke. ThromboGenics is also
developing novel antibody therape...
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
...nd eye diseases. The Company has several programs in Phase II clinical
development including microplasmin, which is being evaluated as a treatment
for
vitreoretinal disorders and as a thrombolytic agent for vascular
occlusive diseases, including acute stroke. ThromboGenics is also
developing novel antibody therape...
Vitreoretinal in Biological Dictionary
Retina
...ll retinal disorders including macular degeneration, macular hole and pucker, diabetic retinopathy, and retinal detachment. Specialists in treating
vitreoretinal disease, macular degeneration, and diabetic retinopathy. ...